Apellis Pharmaceuticals (APLS) Financial Analysis & Valuation | Quarter Chart
Apellis Pharmaceuticals (APLS)
APLSPrice: $41.03
Fair Value: 🔒
🔒score
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pe... more
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discover... more
Description
Shares
| Market Cap | $5.25B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Cedric Francois |
| IPO Date | 2017-11-09 | CAGR | — |
| Employees | 705 | Website | www.apellis.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
APLS chart loading...
Fundamentals
Technicals
| Enterprise Value | $5.14B | P/E Ratio | 38.35 |
| Forward P/E | -130.55 | PEG Ratio | — |
| P/S Ratio | 4.75 | P/B Ratio | 12.46 |
| P/CF Ratio | 136.9 | P/FCF Ratio | 139.04 |
| EPS | $1.07 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 42.46% | Gross Margin | 0.9% |
| Operating Margin | 0.15% | Profit Margin | 0.12% |
| ROE | 0.4% | ROA | 0.12% |
| ROCE | 0.21% | Current Ratio | 3.63 |
| Quick Ratio | 3.16 | Cash Ratio | 1.43 |
| Debt/Equity | 1.15 | Interest Coverage | 3.79 |
| Altman Z Score | 3.23 | Piotroski Score | 6 |